References
- WHO - International Agency for Reasearch on Cancer. Globocan [Internet]. 2020 cited 2021 Oct 2. cited 2021 Oct 2: https://gco.iarc.fr/today/data/factsheets/cancers/30-Bladder-fact-sheet.pdf
- Sanli O, Dobruch J, Knowles MA, et al. Bladder cancer. Nat Rev Dis Prim. 2017;3:17022.
- Smith AB, Deal AM, Woods ME, et al. Muscle-invasive bladder cancer: evaluating treatment and survival in the National cancer data base. BJU Int. [Internet]. 2014;114:719–726. Available from.https://onlinelibrary.wiley.com/doi/10.1111/bju.12601
- Burger M, Catto JWF, Dalbagni G, et al. Epidemiology and risk factors of urothelial bladder cancer. Eur Urol [Internet]. 2013;63:234–241. Available from: https://linkinghub.elsevier.com/retrieve/pii/S0302283812008780
- Kirkali Z, Chan T, Manoharan M, et al. Bladder cancer: epidemiology, staging and grading, and diagnosis. Urology. 2005;66:4–34.
- Jordan B, Meeks JJ. T1 bladder cancer: current considerations for diagnosis and management. Nat Rev Urol. [Internet]. 2019;16:23–34. Available from: http://www.nature.com/articles/s41585-018-0105-y
- Sylvester RJ, Van Der Meijden APM, Oosterlinck W, et al. Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials. Eur Urol. 2006;49:466–477.
- Chamie K, Litwin MS, Bassett JC, et al. Recurrence of high-risk bladder cancer: a population-based analysis. Cancer. 2013;119:3219–3227.
- Babjuk M, Burger M, Capoun O, et al. European association of urology guidelines on non–muscle-invasive bladder cancer (Ta, T1, and Carcinoma in Situ) [Internet]. Eur. Urol. 2021 cited 2021 Oct 2. Available from: https://uroweb.org/guideline/non-muscle-invasive-bladder-cancer/
- Morales A, Eidinger D, Bruce AW. Intracavitary bacillus calmette guerin in the treatment of superficial bladder tumors. J Urol. 1976;116:180–182.
- Hussain MHA, Wood DP, Bajorin DF, et al. Bladder cancer: narrowing the gap between evidence and practice. J Clin Oncol. [Internet]. 2009;27:5680–5684. Available from: http://ascopubs.org/doi/10.1200/JCO.2009.23.6901
- Oddens J, Brausi M, Sylvester R, et al. Final results of an EORTC-GU cancers group randomized study of maintenance bacillus calmette-guérin in intermediate- and high-risk Ta, T1 papillary carcinoma of the urinary bladder: one-third dose versus full dose and 1 year versus 3 years of maintenance. Eur Urol [Internet]. 2013;63:462–472. Available from: https://linkinghub.elsevier.com/retrieve/pii/S0302283812012705
- FD Highlights of prescribing information: valstar (valrubicin) [Internet]. 2016 cited 2021 Oct 2. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/020892s019lbl.pdf.
- FDA. Highlights of prescribing information: keytruda (pembrolizumab) [Internet]. 2020 cited 2021 Oct 2. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125514s066lbl.pdf.
- Bellmunt J, Orsola A, Leow JJ, et al. Bladder cancer: ESMO practice guidelines for diagnosis, treatment and follow-up. Ann Oncol [Internet]. 2014;25:iii40–iii48. Available from https://linkinghub.elsevier.com/retrieve/pii/S0923753419340840
- NCCN.Bladder cancer guidelines.J Am Med Assoc. [Internet]. 1999;282:1908. Available from: https://www.nccn.org/professionals/physician_gls/pdf/bladder.pdf
- Chang SS, Boorjian SA, Chou R, et al. Diagnosis and treatment of non-muscle invasive bladder cancer: AUA/SUO guideline. J Urol [Internet]. 2016;196:1021–1029. Available from: http://www.jurology.com/doi/10.1016/j.juro.2016.06.049
- Tang DH, Chang SS. Management of carcinoma in situ of the bladder: best practice and recent developments. Ther Adv Urol [Internet]. 2015;7:351–364. Available from: http://journals.sagepub.com/doi/10.1177/1756287215599694
- Sylvester RJ, Oosterlinck W, Der Meijden APM V. A single immediate postoperative instillation of chemotherapy decreases the risk of recurrence in patients with stage Ta T1 bladder cancer: a meta-analysis of published results of randomized clinical trials. J Urol [Internet]. 2004;171:2186–2190. Available from: http://www.jurology.com/doi/10.1097/01.ju.0000125486.92260.b2
- Perlis N, Zlotta AR, Beyene J, et al. Immediate post-transurethral resection of bladder tumor intravesical chemotherapy prevents non-muscle-invasive bladder cancer recurrences: an updated meta-analysis on 2548 patients and quality-of-evidence review. Eur Urol [Internet]. 2013;64:421–430. Available from: https://linkinghub.elsevier.com/retrieve/pii/S0302283813006076
- Lamm DL, Blumenstein BA, Crissman JD, et al. Maintenance bacillus Calmette-Guerin immunotherapy for recurrent Ta, T1 and carcinoma in situ transitional cell carcinoma of the bladder: a randomized southwest oncology group study. J Urol. [Internet]. 2000;163:1124–1129. Available from: http://www.jurology.com/doi/10.1016/S0022-5347/2805/2967707-5
- Weinstein JN, Akbani R, Broom BM, et al. Comprehensive molecular characterization of urothelial bladder carcinoma. Nature. [Internet]. 2014;507:315–322. Available from: http://www.nature.com/articles/nature12965
- Ramírez-Backhaus M, Domínguez-Escrig J, Collado A, et al. Restaging transurethral resection of bladder tumor for high-risk stage Ta and T1 bladder cancer. Curr Urol Rep. [Internet]. 2012;13:109–114. Available from: https://link.springer.com/10.1007/s11934-012-0234-4
- Sfakianos JP, Kim PH, Hakimi AA, et al. The effect of restaging transurethral resection on recurrence and progression rates in patients with nonmuscle invasive bladder cancer treated with intravesical bacillus Calmette-Guérin. J Urol. [Internet]. 2014;191:341–345. Available from: http://www.jurology.com/doi/10.1016/j.juro.2013.08.022
- Oddens JR, Sylvester RJ, Brausi MA, et al. Increasing age is not associated with toxicity leading to discontinuation of treatment in patients with urothelial non-muscle-invasive bladder cancer randomised to receive 3 years of maintenance bacille calmette–Guérin: results from European organisation. BJU Int. [Internet]. 2016;118:423–428. Available from: https://onlinelibrary.wiley.com/doi/10.1111/bju.13474
- Kikuchi E, Hayakawa N, Fukumoto K, et al. Bacillus Calmette–Guérin-unresponsive non-muscle-invasive bladder cancer: its definition and future therapeutic strategies. Int J Urol. [Internet]. 2020;27:108–116. Available from: https://onlinelibrary.wiley.com/doi/10.1111/iju.14153
- Van Den Bosch S, Witjes JA. Long-term cancer-specific survival in patients with high-risk, non-muscle-invasive bladder cancer and tumour progression: a systematic review. Eur Urol. [Internet]. 2011;60:493–500. Available from: https://linkinghub.elsevier.com/retrieve/pii/S0302283811005501
- Kamat AM, Hahn NM, Efstathiou JA, et al. Bladder cancer. Lancet [Internet]. 2016;388:2796–2810. Available from: https://linkinghub.elsevier.com/retrieve/pii/S0140673616305128
- Kamat AM, Sylvester RJ, Böhle A, et al. Definitions, end points, and clinical trial designs for non-muscle-invasive bladder cancer: recommendations from the International bladder cancer group. J Clin Oncol. [Internet]. 2016;34:1935–1944. Available from: https://ascopubs.org/doi/10.1200/JCO.2015.64.4070
- Nieder AM, Simon MA, Kim SS, et al. Radical cystectomy after bacillus Calmette-Guérin for high-risk Ta, T1, and carcinoma in situ: defining the risk of initial bladder preservation. Urology [Internet]. 2006;67:737–741. Available from: https://linkinghub.elsevier.com/retrieve/pii/S0090429505014676
- Denzinger S, Fritsche HM, Otto W, et al. Early versus deferred cystectomy for initial high-risk pT1G3 urothelial carcinoma of the bladder: do risk factors define feasibility of bladder-sparing approach? Eur Urol. [Internet]. 2008;53:146–152. Available from: https://linkinghub.elsevier.com/retrieve/pii/S0302283807008652
- Kakiashvili DM, Van Rhijn BWG, Trottier G, et al. Long-term follow-up of T1 high-grade bladder cancer after intravesical bacille Calmette-Guérin treatment. BJU Int. [Internet]. 2011;107:540–546. Available from: https://onlinelibrary.wiley.com/doi/10.1111/j.1464-410X.2010.09572.x
- Dinney CPN, Greenberg RE, Steinberg GD. Intravesical valrubicin in patients with bladder carcinoma in situ and contraindication to or failure after bacillus Calmette-Guérin. Urol Oncol Semin Orig Investig. [Internet]. 2013;31:1635–1642. Available from: https://linkinghub.elsevier.com/retrieve/pii/S1078143912001512
- Steinberg RL, Thomas LJ, Brooks N, et al. Multi-institution evaluation of sequential gemcitabine and docetaxel as rescue therapy for nonmuscle invasive bladder cancer. J Urol. [Internet]. 2020;203:902–909. Available from: https://www.jurology.com/doi/10.1097/JU.0000000000000688
- Basile G, Pederzoli F, Bandini M, et al. Intermediate- and high-risk nonmuscle invasive bladder cancer: where do we stand? Urol Oncol Semin Orig Investig. [Internet]. 2021;39:631–641. Available from: https://linkinghub.elsevier.com/retrieve/pii/S1078143921000818
- Shore ND, Palou Redorta J, Robert G, et al. Non-muscle-invasive bladder cancer: an overview of potential new treatment options. Urol Oncol Semin Orig Investig. [Internet]. 2021;39:642–663. Available from: https://linkinghub.elsevier.com/retrieve/pii/S1078143921002210
- Choi W, Czerniak B, Ochoa A, et al. Intrinsic basal and luminal subtypes of muscle-invasive bladder cancer. Nat Rev Urol [Internet]. 2014;11:400–410. Available from: http://www.nature.com/articles/nrurol.2014.129
- Robertson AG, Kim J, Al-Ahmadie H, et al. Comprehensive molecular characterization of muscle-invasive bladder cancer. Cell. [Internet]. 2017;171:540–556.e25. Available from: https://linkinghub.elsevier.com/retrieve/pii/S0092867417310565
- McConkey DJ, Choi W, Shen Y, et al. A prognostic gene expression signature in the molecular classification of chemotherapy-naïve urothelial cancer is predictive of clinical outcomes from neoadjuvant chemotherapy: a phase 2 trial of dose-dense methotrexate, vinblastine, doxorubicin, and cisp. Eur Urol. [Internet]. 2016;69:855–862. Available from: https://linkinghub.elsevier.com/retrieve/pii/S0302283815007794
- McConkey DJ, Choi W, Ochoa A, et al. Therapeutic opportunities in the intrinsic subtypes of muscle-invasive bladder cancer. Hematol Oncol Clin North Am. [Internet]. 2015;29:377–394. Available from: https://linkinghub.elsevier.com/retrieve/pii/S0889858814001725
- Rosenberg JE, Hoffman-Censits J, Powles T, et al. Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial. Lancet. [Internet]. 2016;387:1909–1920. Available from: https://linkinghub.elsevier.com/retrieve/pii/S0140673616005614
- Sharma P, Retz M, Siefker-Radtke A, et al. Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multicentre, single-arm, phase 2 trial. Lancet Oncol. [Internet]. 2017;18:312–322. Available from: https://linkinghub.elsevier.com/retrieve/pii/S1470204517300657
- V BA, Galsky MD, Rosenberg JE, et al. Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial. Lancet. [Internet]. 2017;389:67–76. Available from: https://linkinghub.elsevier.com/retrieve/pii/S0140673616324552
- Powles T, Durán I, van der Heijden MS, et al. Atezolizumab versus chemotherapy in patients with platinum-treated locally advanced or metastatic urothelial carcinoma (IMvigor211): a multicentre, open-label, phase 3 randomised controlled trial. Lancet. [Internet]. 2018;391:748–757. Available from: https://linkinghub.elsevier.com/retrieve/pii/S014067361733297X
- Sharma P, Callahan MK, Bono P, et al. Nivolumab monotherapy in recurrent metastatic urothelial carcinoma (CheckMate 032): a multicentre, open-label, two-stage, multi-arm, phase 1/2 trial. Lancet Oncol. [Internet]. 2016;17:1590–1598. Available from: https://linkinghub.elsevier.com/retrieve/pii/S147020451630496X
- Holm JS, Funt SA, Bjerregaard A-M, et al. Interrogation of neoantigen-specific CD8 T cells in peripheral blood following PD-L1 blockade in patients with metastatic urothelial carcinoma (mUC). J Clin Oncol. [Internet]. 2020;38:3075. Available from: https://ascopubs.org/doi/10.1200/JCO.2020.38.15_suppl.3075
- Inman BA, Sebo TJ, Frigola X, et al. PD-L1 (B7-H1) expression by urothelial carcinoma of the bladder and BCG-induced granulomata: associations with localized stage progression. Cancer. [Internet]. 2007;109:1499–1505. Available from: https://onlinelibrary.wiley.com/doi/10.1002/cncr.22588
- Nakanishi J, Wada Y, Matsumoto K, et al. Overexpression of B7-H1 (PD-L1) significantly associates with tumor grade and postoperative prognosis in human urothelial cancers. Cancer Immunol Immunother. [Internet]. 2007;56:1173–1182. Available from: http://link.springer.com/10.1007/s00262-006-0266-z
- der Meer Jmr V, Maas RJA, Guldevall K, et al. IL-15 superagonist N-803 improves IFNγ production and killing of leukemia and ovarian cancer cells by CD34+ progenitor-derived NK cells. Cancer Immunol Immunother. [Internet]. 2021;70:1305–1321. Available from: https://link.springer.com/10.1007/s00262-020-02749-8
- Chamie K, Lee JH, Rock A, et al. Preliminary phase 2 clinical results of IL-15RαFc superagonist N-803 with BCG in BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) patients. J Clin Oncol. [Internet]. 2019;37:4561. Available from: http://ascopubs.org/doi/10.1200/JCO.2019.37.15_suppl.4561
- Chamie K, Chang S, Gonzalgo ML, et al. Phase II/III clinical results of IL-15RαFc superagonist N-803 with BCG in BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) carcinoma in situ (CIS) patients. J Clin Oncol. [Internet]. 2021;39:510. Available from: https://ascopubs.org/doi/10.1200/JCO.2021.39.6_suppl.510
- Ji N, Mukherjee N, Reyes RM, et al. Rapamycin enhances BCG-specific 3δT cells during intravesical BCG therapy for non-muscle invasive bladder cancer: a randomized, double-blind study. J Immunother Cancer. [Internet]. 2021;9:e001941. Available from: https://jitc.bmj.com/lookup/doi/10.1136/jitc-2020-001941
- Ross RL, McPherson HR, Kettlewell L, et al. PIK3CA dependence and sensitivity to therapeutic targeting in urothelial carcinoma. BMC Cancer. [Internet]. 2016;16:553. Available from: http://bmccancer.biomedcentral.com/articles/10.1186/s12885-016-2570-0
- Boorjian SA, Alemozaffar M, Konety BR, et al. Intravesical nadofaragene firadenovec gene therapy for BCG-unresponsive non-muscle-invasive bladder cancer: a single-arm, open-label, repeat-dose clinical trial. Lancet Oncol. [Internet]. 2021;22:107–117. Available from: https://linkinghub.elsevier.com/retrieve/pii/S1470204520305404
- Shore ND, Boorjian SA, Canter DJ, et al. Intravesical rAd–IFNa/Syn3 for patients with high-grade, bacillus calmette-guerin–refractory or relapsed non–muscle-invasive bladder cancer: a phase II randomized study. J Clin Oncol. [Internet]. 2017;35:3410–3416. Available from: https://ascopubs.org/doi/10.1200/JCO.2017.72.3064
- Sidi AA, Ohana P, Benjamin S, et al. Phase I/II marker lesion study of intravesical BC-819 DNA plasmid in H19 over expressing superficial bladder cancer refractory to bacillus Calmette-Guerin. J Urol. [Internet]. 2008;180:2379–2383. Available from: http://www.jurology.com/doi/10.1016/j.juro.2008.08.006
- Halachmi S, Leibovitch I, Zisman A, et al. Phase II trial of BC-819 intravesical gene therapy in combination with BCG in patients with non-muscle invasive bladder cancer (NMIBC). J Clin Oncol. [Internet]. 2018;36:499. Available from: https://ascopubs.org/doi/10.1200/JCO.2018.36.6_suppl.499
- Flippot R, Beinse G, Boilève A, et al. Long non-coding RNAs in genitourinary malignancies: a whole new world. Nat Rev Urol [Internet]. 2019;16:484–504. Available from: http://www.nature.com/articles/s41585-019-0195-1
- Obara W, Hara I, Kato Y, et al. Immunotherapy with cancer peptides in combination with intravesical bacillus Calmette–Guerin for patients with non-muscle invasive bladder cancer. Cancer Immunol Immunother. [Internet]. 2018;67:1371–1380. Available from: http://link.springer.com/10.1007/s00262-018-2197-x
- Obara W. Adjuvant cancer peptide vaccine treatment with intravesical BCG therapy for non-muscle-invasive bladder cancer. J Clin Oncol. [Internet]. 2013;31:e15587–e15587. Available from: http://ascopubs.org/doi/10.1200/jco.2013.31.15_suppl.e15587
- Steinberg GD, Shore ND, Karsh LI, et al. Immune response results of vesigenurtacel-l (HS-410) in combination with BCG from a randomized phase II trial in patients with non-muscle invasive bladder cancer (NMIBC). J Clin Oncol. [Internet]. 2017;35:319. Available from: https://ascopubs.org/doi/10.1200/JCO.2017.35.6_suppl.319
- Steinberg GD, Shore N, Karsh L, et al. A phase I/II study of vesigenurtacel-l (hs-410) or placebo in combination with Bacillus Calmette-Guérin (BCG) in patients with non-muscle invasive bladder cancer (NMIBC). J Immunother Cancer. [Internet]. 2014;2:P81. Available from: https://jitc.bmj.com/lookup/doi/10.1186/2051-1426-2-S3-P81
- Lindskrog SV, Prip F, Lamy P, et al. An integrated multi-omics analysis identifies prognostic molecular subtypes of non-muscle-invasive bladder cancer. Nat Commun. [Internet]. 2021;12:2301. Available from: http://www.nature.com/articles/s41467-021-22465-w
- van Kessel Kem, van der Keur Ka, Dyrskjøt L, et al. Molecular markers increase precision of the European Association of urology non–muscle-invasive bladder cancer progression risk groups. Clin Cancer Res. [Internet]. 2018;24:1586–1593. Available from: http://clincancerres.aacrjournals.org/lookup/doi/10.1158/1078-0432.CCR-17-2719
- Babina IS, Turner NC. Advances and challenges in targeting FGFR signalling in cancer. Nat Rev Cancer. [Internet]. 2017;17:318–332. Available from: http://www.nature.com/articles/nrc.2017.8
- Nassar AH, Umeton R, Kim J, et al. Mutational analysis of 472 urothelial carcinoma across grades and anatomic sites. Clin Cancer Res. [Internet]. 2019;25:2458–2470. Available from: http://clincancerres.aacrjournals.org/lookup/doi/10.1158/1078-0432.CCR-18-3147
- Pietzak EJ, Bagrodia A, Cha EK, et al. next-generation sequencing of nonmuscle invasive bladder cancer reveals potential biomarkers and rational therapeutic targets. Eur Urol. [Internet]. 2017;72:952–959. Available from: https://linkinghub.elsevier.com/retrieve/pii/S0302283817304669
- Kilgour E, Angell H, Smith NR, et al. Fibroblast growth factor receptor 3 (FGFR3) mutant muscle invasive bladder cancers (MIBC) are associated with low immune infiltrates. Ann Oncol. [Internet]. 2016;27:vi272. Available from: https://linkinghub.elsevier.com/retrieve/pii/S0923753419444141
- Loriot Y, Necchi A, Park SH, et al. Erdafitinib in locally advanced or metastatic urothelial carcinoma. N Engl J Med. [Internet]. 2019;381:338–348. Available from: http://www.nejm.org/doi/10.1056/NEJMoa1817323
- Steinberg GD, Palou-Redorta J, Gschwend JE, et al. A randomized phase II study of erdafitinib (ERDA) versus intravesical chemotherapy (IC) in patients with high-risk nonmuscle invasive bladder cancer (HR-NMIBC) with FGFR mutations or fusions, who recurred after Bacillus Calmette-Guérin (BCG) therapy. J Clin Oncol. [Internet]. 2020;38 6_suppl: TPS603-TPS603. Available from: https://ascopubs.org/doi/10.1200/JCO.2020.38.6_suppl.TPS603
- Mazzola CR, Siddiqui KM, Billia M, et al. Dovitinib: rationale, preclinical and early clinical data in urothelial carcinoma of the bladder. Expert Opin Investig Drugs. [Internet]. 2014;23:1553–1562. Available from: http://www.tandfonline.com/doi/full/10.1517/13543784.2014.966900
- Pal SK, Bajorin D, Dizman N, et al. Infigratinib in upper tract urothelial carcinoma versus urothelial carcinoma of the bladder and its association with comprehensive genomic profiling and/or cell-free DNA results. Cancer. [Internet]. 2020;126:2597–2606. Available from: https://onlinelibrary.wiley.com/doi/10.1002/cncr.32806
- Hahn NM, Bivalacqua TJ, Ross AE, et al. A phase II trial of dovitinib in BCG-unresponsive urothelial carcinoma with FGFR3 mutations or overexpression: Hoosier cancer research network trial HCRN 12-157. Clin Cancer Res. [Internet]. 2017;23:3003–3011. Available from: http://clincancerres.aacrjournals.org/lookup/doi/10.1158/1078-0432.CCR-16-2267
- Zahoor H, Mir MC, Barata PC, et al. Phase II trial of continuous treatment with sunitinib in patients with high-risk (BCG-refractory) non-muscle invasive bladder cancer. Invest New Drugs. [Internet]. 2019;37:1231–1238. Available from: http://link.springer.com/10.1007/s10637-018-00716-w
- Santoni M, Amantini C, Morelli MB, et al. Pazopanib and sunitinib trigger autophagic and non-Autophagic death of bladder tumour cells. Br J Cancer. [Internet]. 2013;109:1040–1050. Available from: http://www.nature.com/articles/bjc2013420
- Ping SY, Wu CL, Yu DS. Sunitinib can enhance BCG mediated cytotoxicity to transitional cell carcinoma through apoptosis pathway. Urol Oncol Semin Orig Investig. [Internet]. 2012;30:652–659. Available from: https://linkinghub.elsevier.com/retrieve/pii/S1078143910001754
- Shim JS, Matsui Y, Bhat S, et al. Effect of nitroxoline on angiogenesis and growth of human bladder cancer. J Natl Cancer Inst. [Internet]. 2010;102:1855–1873. Available from: https://academic.oup.com/jnci/article-lookup/doi/10.1093/jnci/djq457
- Godoy G, Gakis G, Smith CL, et al. Effects of androgen and estrogen receptor signaling pathways on bladder cancer initiation and progression. Bl Cancer. [Internet]. 2016;2:127–137. Available from: https://www.medra.org/servlet/aliasResolver?alias=iospress&doi=10.3233/BLC-160052
- Siddiqui MR, Grant C, Sanford T, et al. Current clinical trials in non–muscle invasive bladder cancer. Urol Oncol Semin Orig Investig. [Internet]. 2017;35:516–527. Available from: https://linkinghub.elsevier.com/retrieve/pii/S1078143917303034
- Brunner A, Prelog M, Verdorfer I, et al. EpCAM is predominantly expressed in high grade and advanced stage urothelial carcinoma of the bladder. J Clin Pathol. [Internet]. 2008;61:307–310. Available from: http://jcp.bmj.com/cgi/doi/10.1136/jcp.2007.049460
- Kowalski M, Guindon J, Brazas L, et al. A phase II study of oportuzumab monatox: an immunotoxin therapy for patients with noninvasive urothelial carcinoma in situ previously treated with bacillus Calmette-Guérin. J Urol. [Internet]. 2012;188:1712–1718. Available from: http://www.jurology.com/doi/10.1016/j.juro.2012.07.020
- V BA, Kamat AM, Kulkarni GS, et al.Pembrolizumab monotherapy for the treatment of high-risk non-muscle-invasive bladder cancer unresponsive to BCG (KEYNOTE-057): an open-label, single-arm, multicentre, phase 2 study.Lancet Oncol. [Internet]. 2021;22:919–930. Available from: https://linkinghub.elsevier.com/retrieve/pii/S1470204521001479
- Corp. U of OS& D. Pembrolizumab in intermediate risk recurrent non-muscle invasive bladder cancer (NMIBC) [Internet]. Clinicaltrials.Gov. 2019 [cited 2021 Oct 2]. 2017 Jul 31-Aug-21. Available from: https://clinicaltrials.gov/show/NCT03167151
- Black PC, Tangen C, Singh P, et al. Phase II trial of atezolizumab in BCG-unresponsive non-muscle invasive bladder cancer: SWOG S1605 (NCT #02844816), J Clin Oncol [Internet]. 2021;39:4541. Available from: https://ascopubs.org/doi/10.1200/JCO.2021.39.15_suppl.4541
- Alanee S, El ZA, Sana S, et al. Abstract CT047: phase I trial of intravesical Bacillus Calmette-Guérin combined with intravenous Pembrolizumab in high grade nonmuscle invasive bladder cancer. Clin Trials [Internet]. American Association for Cancer Research; 2019. p. CT047–CT047. Available from: http://cancerres.aacrjournals.org/lookup/doi/10.1158/1538-7445.AM2019-CT047
- Cookson M, Tripathi A, Patel S, et al. Lba02-04 novel weekly immunotherapy dosing with avelumab tolerated during Bacillus Calmette-Guerin induction therapy: initial results of the Abc trial. J Urol. [Internet]. 2021;206. Available from: http://www.jurology.com/doi/10.1097/JU.0000000000002149.04
- Hahn NM, O'Donnell, MA, Efstathiou, JA, et al. Phase 1 trial of durvalumab in combination with BCG or external beam radiation in BCG-unresponsive non muscle invasive blasser cancer patients (HCRN GU16-243: ADAPT-BLADDER trial). SUO - 21st Annu Meet. [Internet]. 2020; Poster #22 Available from: https://suo-abstracts.secure-platform.com/a/gallery/rounds/9/details/876
- Narayan V, Boorjian S, Alemozaffer M, et al. Subgroup analyses of the phase 3 study of intravesical nadofaragene firadenovec in patients with high-grade, BCG-unresponsive Non-muscle invasive bladder cancer (NMIBC). Eur Urol [Internet]. 2021;79:S1026–S1027. Available from: https://suo-abstracts.secure-platform.com/a/gallery/rounds/9/details/1373
- Institute for Clinical and Economic Review. Nadofaragene firadenovec and oportuzumab monatox for BCG-unresponsive, Non-Muscle invasive bladder cancer: effectiveness and value. [Internet]. 2020 cited 2021 Oct 2. Available from: https://icer.org/wp-content/uploads/2020/08/ICER_Bladder_Cancer_Final_Report_122220-1.pdf
- Gofrit ON, Benjamin S, Halachmi S, et al. DNA based therapy with diphtheria toxin-a BC-819: a phase 2b marker lesion trial in patients with intermediate risk nonmuscle invasive bladder cancer. J Urol. [Internet]. 2014;191:1697–1702. Available from: http://www.jurology.com/doi/10.1016/j.juro.2013.12.011
- Codex: study of inodiftagene vixteplasmid (BC-819) in unresponsive NMIBC. ClinicalTrials.gov identifier: NCT03719300 [Internet]. ClinicalTrials.gov. 2020 cited 2021 Oct 2. Available from: https://clinicaltrials.gov/ct2/show/results/NCT03719300?term=BC-819&draw=2&rank=1
- EG-70 in patients with BCG-Unresponsive NMIBC (LEGEND STUDY) - NCT04752722. [Internet]. ClinicalTrials.gov. 2021 cited 2021 Oct 2. Available from: 2021 Oct 2: https://clinicaltrials.gov/ct2/show/NCT04752722
- Bivalacqua T Trial design considerations for intermediate Risk non muscle-invasive bladder cancer [Internet]. urotoday.com. 2021[cited 2022 Oct 2]. Available from: https://www.urotoday.com/conference-highlights/nmibc-2021/128353-trial-design-considerations-for-intermediate-risk-non-muscle-invasive-bladder-cancer.html
- Packiam VT, Lamm DL, Barocas DA, et al. An open label, single-arm, phase II multicenter study of the safety and efficacy of CG0070 oncolytic vector regimen in patients with BCG-unresponsive non–muscle-invasive bladder cancer: interim results. Urol Oncol Semin Orig Investig. [Internet]. 2018;36:440–447. Available from: https://linkinghub.elsevier.com/retrieve/pii/S1078143917303502
- Study of CG0070 given in patients with Non-muscle invasive bladder cancer, unresponsive to Bacillus-Calmette-Guerin (BOND-003) - NCT04452591 [Internet]. ClinicalTrials.gov. 2020 cited 2021 Oct 2. Available from: https://clinicaltrials.gov/ct2/show/NCT04452591
- Pandha HS, Annels NE, Simpson G, et al. Phase I/II canon study: oncolytic immunotherapy for the treatment of non-muscle invasive bladder (NMIBC) cancer using intravesical coxsackievirus A21. J Clin Oncol. [Internet]. 2016;34:e16016–e16016. Available from: http://ascopubs.org/doi/10.1200/JCO.2016.34.15_suppl.e16016
- Annels NE, Mansfield D, Arif M, et al. Phase I trial of an ICAM-1-targeted immunotherapeutic-coxsackievirus A21 (CVA21) as an oncolytic agent against non muscle-invasive bladder cancer. Clin Cancer Res. [Internet]. 2019;25:5818–5831. Available from: http://clincancerres.aacrjournals.org/lookup/doi/10.1158/1078-0432.CCR-18-4022
- CAVATAK (CVA21) in Non-muscle invasive bladder cancer (VLA-012 CANON) (CANON) - NCT02316171. [Internet]. ClinicalTrials.gov. 2019; cited 2021 Oct 2. Available from. Available from: https://clinicaltrials.gov/ct2/show/results/NCT02316171?term=CVA21&cond=non+muscle+invasive+bladder+cancer&draw=2&rank=1
- Saoud R, Telfer S, Maruf M, et al. Mp16-14 clinical outcomes of a randomized, prospective, phase ii study to determine the efficacy of Bacillus Calmette-Guerin (Bcg) given in combination with panvac versus bcg given alone in adults with high grade Bcg-refractory non-muscle invasive bladder. J Urol. [Internet]. 2021;206. Available from.;. http://www.jurology.com/doi/10.1097/JU.0000000000002001.14
- Derré L, Cesson V, Lucca I, et al. Intravesical bacillus calmette guerin combined with a cancer vaccine increases local T-cell responses in non-muscle-invasive bladder cancer patients. Clin Cancer Res. [Internet]. 2017;23:717–725. Available from: http://clincancerres.aacrjournals.org/lookup/doi/10.1158/1078-0432.CCR-16-1189
- Domingos-Pereira S, Sathiyanadan K, La Rosa S, et al. Intravesical Ty21a vaccine promotes dendritic cells and T cell–mediated tumor regression in the MB49 bladder cancer model. Cancer Immunol Res. [Internet]. 2019;7:621–629. Available from: http://cancerimmunolres.aacrjournals.org/lookup/doi/10.1158/2326-6066.CIR-18-0671
- Rosser CJ, Nix J, Ferguson L, et al. Phase Ib trial of ALT-803, an IL-15 superagonist, plus BCG for the treatment of BCG-naïve patients with non-muscle-invasive bladder cancer. J Clin Oncol. [Internet]. 2018;36:510. Available from: https://ascopubs.org/doi/10.1200/JCO.2018.36.6_suppl.510
- FDA breakthrough therapy designation for N-803 [Internet]. businneswire.com. 2019. Available from: https://www.businesswire.com/news/home/20191204005300/en/ImmunityBio-Granted-FDA-Breakthrough-Therapy-Designation-for-N-803-IL-15-Superagonist-in-Non-Muscle-Invasive-Bladder-Cancer.
- Sonpavde G, Rosser CJ, Pan C, et al. Phase I trial of ALT-801, a first-in-class T-cell receptor (TCR)-interleukin (IL)-2 fusion molecule, plus gemcitabine (G) for Bacillus Calmette Guerin (BCG)-resistant non-muscle-invasive bladder cancer (NMIBC). J Clin Oncol. [Internet]. 2015;33:e15509–e15509. Available from: http://ascopubs.org/doi/10.1200/jco.2015.33.15_suppl.e15509
- Donin NM, Chamie K, Lenis AT, et al. A phase 2 study of TMX-101, intravesical imiquimod, for the treatment of carcinoma in situ bladder cancer. Urol Oncol Semin Orig Investig. [Internet]. 2017;35:39.e1–39.e7. Available from: https://linkinghub.elsevier.com/retrieve/pii/S1078143916302745
- Oral Lenalidomide and Intravesical BCG for therapy of bladder cancer - full text view - clinicaltrials.gov [Internet]. ClinicalTrials.gov. 2016 cited 2021 Oct 2. 2021 Oct 2. Available from: http://clinicaltrials.gov/show/NCT01373294
- McKiernan JM, Onyeji I, Lascano D, et al. A phase I/II study of albumin-bound rapamycin nanoparticles in the treatment of bacillus calmette-guerin refractory non-muscle invasive transitional cell bladder cancer. J Clin Oncol. [Internet]. 2016;34:e16008–e16008. Available from: http://ascopubs.org/doi/10.1200/JCO.2016.34.15_suppl.e16008
- Prendergast GC, Smith C, Thomas S, et al. Indoleamine 2,3-dioxygenase pathways of pathogenic inflammation and immune escape in cancer. Cancer Immunol Immunother. [Internet]. 2014;63:721–735. Available from: http://link.springer.com/10.1007/s00262-014-1549-4
- Hancock BM, McGuire KL, Tsuji S, et al. A single intravesical instillation of VAX014 inhibits orthotopic superficial bladder tumor implantation to increase survival. Anticancer Res. [Internet]. 2016;36:6243–6248. Available from: http://ar.iiarjournals.org/content/36/12/6243.abstract
- Shore N, O’Donnell M, Keane T, et al. Pd03-02 phase 3 results of vicinium in Bcg-unresponsive Non-muscle invasive bladder cancer. J Urol. [Internet]. 2020;203: 743–750. Available from: http://www.jurology.com/doi/10.1097/JU.0000000000000823.02
- O’Donnell M, Shore N, Keane T, et al. Mp16-03 phase 3 study of vicineum in Bcg-Unresponsive Non-Muscle invasive bladder cancer: 24-Month results. J Urol. [Internet]. 2021;206. Available from: http://www.jurology.com/doi/10.1097/JU.0000000000002001.03
- Vicinium granted fast track designation FDA [Internet]. Sesenbio. 2018. Available from: https://sesenbio.gcs-web.com/news-releases/news-release-details/sesen-bio-announces-vicinium-granted-fast-track-designation-fda
- Sesen bio announces FDA acceptance and priority review of its biologics license application for vicineumTM. [Internet]. Sesen Bio Press Release. 2021. Available from: https://www.businesswire.com/news/home/20210216005637/en/Sesen-Bio-Announces-FDA-Acceptance-and-Priority-Review-of-its-Biologics-License-Application-for-VicineumTM
- Bio S. Sesen bio receives complete response letter from FDA for VICINEUMTM. ( oportuzumab monatox-qqrs) [Internet]. 2021. Available from: https://ir.sesenbio.com/news-releases/news-release-details/sesen-bio-receives-complete-response-letter-fda-vicineumtm
- Gurram S, Bellfield S, Dolan R, et al. Pd09-04 interim analysis of a phase I single-arm study of the combination of durvalumab (Medi4736) and vicinium (Oportuzumab Monatox, Vb4-845) in subjects with high-grade Non-Muscle-invasive bladder cancer previously treated with Bacillus Calmette-Guerin. J Urol. [Internet]. 2021;206. Available from: http://www.jurology.com/doi/10.1097/JU.0000000000001977.04
- Walker CH, Lebastchi AH, Russell CM, et al. Pd18-02 increased urinary vascular endothelial growth factor D (Vegf-D) levels are associated with response to combined intravesical Bacillus Calmette−Guerin (Bcg) and oral sunitinib regimen for treatment of high-risk non-muscle invasive bladder cancer (N). J Urol. [Internet]. 2019;201. Available from: http://www.jurology.com/doi/10.1097/01.JU.0000555574.00837.23
- Cha EK, Iyer G, Funt SA, et al. Marker lesion study of oral FGFR inhibitor BGJ398 in patients with FGFR3-altered intermediate-risk nonmuscle-invasive bladder cancer. J Clin Oncol. [Internet]. 2020;38:510. Available from: https://ascopubs.org/doi/10.1200/JCO.2020.38.6_suppl.510
- Sfakianos J, Shore ND, Zhuang J. Phase Ib study: APL-1202 (APL) in combination with Bacillus Calmette-Guerin (BCG) in recurrent non-muscle invasive bladder cancer (NMIBC). J Clin Oncol. [Internet]. 2020;38:e17039–e17039. Available from: https://ascopubs.org/doi/10.1200/JCO.2020.38.15_suppl.e17039
- Godoy G, Wu W, Jo E, et al. Lba-19 phase Ii trial of estrogen receptor targeted treatment of non-muscle invasive bladder cancer with tamoxifen. J Urol. [Internet]. 2019;201. Available from: http://www.jurology.com/doi/10.1097/01.JU.0000557511.69076.80
- Molenaar RJ, Van Hattum JW, Brummelhuis IS, et al. Study protocol of a phase II clinical trial of oral metformin for the intravesical treatment of non-muscle invasive bladder cancer. BMC Cancer. [Internet]. 2019;19:1133. Available from: https://bmccancer.biomedcentral.com/articles/10.1186/s12885-019-6346-1
- Rosenberg J, Sridhar SS, Zhang J, et al. EV-101: a phase I study of single-agent enfortumab vedotin in patients with nectin-4–positive solid tumors, including metastatic urothelial carcinoma. J Clin Oncol. [Internet]. 2020;38:1041–1049. Available from: https://ascopubs.org/doi/10.1200/JCO.19.02044
- FDA grants regular approval to enfortumab vedotin-ejfv for locally advanced or metastatic urothelial cancer. fda.gov. 2021.
- Ruf P, Bauer HW, Schoberth A, et al. First time intravesically administered trifunctional antibody catumaxomab in patients with recurrent non-muscle invasive bladder cancer indicates high tolerability and local immunological activity. Cancer Immunol Immunother. [Internet]. 2021;70:2727–2735. Available from: https://link.springer.com/10.1007/s00262-021-02930-7
- Hien TT, Ambite I, Butler D, et al. Bladder cancer therapy without toxicity—A dose-escalation study of alpha1-oleate. Int J Cancer. [Internet]. 2020;147:2479–2492. Available from: https://onlinelibrary.wiley.com/doi/10.1002/ijc.33019
- Ourfali S, Ohannessian R, Fassi-Fehri H, et al. Recurrence rate and cost consequence of the shortage of bacillus calmette-Guérin Connaught Strain for bladder cancer patients. Eur Urol Focus. [Internet]. 2021;7:111–116. Available from: https://linkinghub.elsevier.com/retrieve/pii/S2405456919301099
- Jarow JP, Lerner SP, Kluetz PG, et al. Clinical trial design for the development of new therapies for nonmuscle-invasive bladder cancer: report of a food and drug administration and American urological association public workshop. Urology. [Internet]. 2014;83:262–265. Available from: https://linkinghub.elsevier.com/retrieve/pii/S0090429513013757
- US Food and Drug Administration. BCG-unresponsive non-muscle invasive bladder cancer: developing drugs and biologics for treatment. Guidance for industry. [Internet]. cited Jul 2020. 2018 Availablefrom: https://www.fda.gov/media/101468/download
- Bellmunt J, Kim J, Reardon B, et al. Genomic predictors of good outcome, recurrence, or progression in high-grade T1 non-muscle-invasive bladder cancer. Cancer Res. [Internet]. 2021;80:4476–4486. Available from: https://cancerres.aacrjournals.org/lookup/doi/10.1158/0008-5472.CAN-20-0977
- Martin-Doyle W, Leow JJ, Orsola A, et al. Improving selection criteria for early cystectomy in high-grade T1 bladder cancer: a meta-analysis of 15,215 patients. J Clin Oncol. [Internet]. 2015;33:643–650. Available from: https://ascopubs.org/doi/10.1200/JCO.2014.57.6967
- Ding X, Chen Q, Yang Z, et al. Clinicopathological and prognostic value of PD-L1 in urothelial carcinoma: a meta-analysis. Cancer Manag Res. [Internet]. 2019;11:4171–4184. Available from: https://www.dovepress.com/clinicopathological-and-prognostic-value-of-pd-l1-in-urothelial-carcin-peer-reviewed-article-CMAR
- Wen Y, Chen Y, Duan X, et al. The clinicopathological and prognostic value of PD-L1 in urothelial carcinoma: a meta-analysis. Clin Exp Med. [Internet]. 2019;19:407–416. Available from: http://link.springer.com/10.1007/s10238-019-00572-9
- Powles T, Assaf ZJ, Davarpanah N, et al. ctDNA guiding adjuvant immunotherapy in urothelial carcinoma. Nature. [Internet]. 2021;595:432–437. Available from: http://www.nature.com/articles/s41586-021-03642-9
- Zhang J, Dai D, Tian J, et al. Circulating tumor DNA analyses predict disease recurrence in Non-muscle-invasive bladder cancer. Front Oncol [Internet]. 2021;11. Available from: https://www.frontiersin.org/articles/10.3389/fonc.2021.657483/full
- Clinton T, et al. Response of FGFR3 alterations in high grade non muscle invasive bladder cancer treated with intravesical BCG therapy [Internet]. SUO - 20th Annu. Meet. 2019. Available from: https://suo-abstracts.secure-platform.com/a/gallery/rounds/1/details/424
- Mazieres J, Drilon A, Lusque A, et al. Immune checkpoint inhibitors for patients with advanced lung cancer and oncogenic driver alterations: results from the IMMUNOTARGET registry. Ann Oncol. [Internet]. 2019;30:1321–1328. Available from: https://linkinghub.elsevier.com/retrieve/pii/S0923753419312840
- Necchi A, Raggi D, Gallina A, et al. Molecular subtyping and immune-gene signatures identify a subset of early bladder tumors as candidates for single-agent immune-checkpoint inhibition. Urol Oncol Semin Orig Investig. [Internet]. 2021;39:734.e11–734.e17. Available from: https://linkinghub.elsevier.com/retrieve/pii/S1078143921002702